Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.35 |
| ▸ | CA1 | P00915 | 9/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014416 | 0.86 | NLRP3 (0.42) | CA2CA1CA12CA7SOAT2 | |
| SCHEMBL22014348 | 0.85 | CA2 (0.32) | CA2CA1CA12CA9CA14 | |
| SCHEMBL22014359 | 0.80 | RORC (0.39) | CA2CA1CA12KMT2ACA9 | |
| SCHEMBL25066900 | 0.76 | SOAT2 (0.31) | CA2CA1CA12SOAT2MYC | |
| SCHEMBL22014844 | 0.76 | NLRP3 (0.35) | SOAT2MYCSOAT1MAP2K3ELANE | |
| SCHEMBL20698755 | 0.75 | NLRP3 (0.35) | SOAT2MYCSOAT1MAP2K3NLRP3 | |
| SCHEMBL20698839 | 0.74 | NLRP3 (0.41) | ALDH1A1SMN1; SMN2NLRP3 | |
| SCHEMBL25067006 | 0.74 | NLRP3 (0.44) | CA2CA1CA12CA7MEN1 | |
| SCHEMBL20698687 | 0.73 | NLRP3 (0.42) | CA2CA1CA12CA7NLRP3 | |
| SCHEMBL22014583 | 0.73 | NLRP3 (0.42) | CA2CA1CA12CA7NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1522/4885CA1 3832/4885CA12 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.